Abdul Mannan

Dr. Abdul Mannan is a Postdoctoral Research Fellow in the Molecular Oncology Group at the School of Biomedical Sciences and Pharmacy, University of Newcastle, Australia. His work focuses on cancer biology, particularly diffuse midline gliomas, acute myeloid leukemia, and pediatric cancers. He investigates genetic dependencies, drug resistance mechanisms, and novel therapeutic strategies through proteogenomics, phosphoproteomics, and drug combination studies.

Research Interests:

• Targeted therapies for diffuse midline gliomas (DMG) and diffuse intrinsic pontine glioma (DIPG)
• Oncogenic signaling pathways (PI3K/mTOR, ROS-driven, JAK/STAT)
• Drug resistance mechanisms in acute myeloid leukemia (AML)
• Phosphoproteomic profiling for real-time drug selection
• Combination therapies (e.g., ONC201 + paxalisib)
• Role of BCL6 in pediatric cancers

Articles Trends: Recent work emphasizes preclinical validation of drug combinations for DMG, phosphoproteomics-driven therapeutic selection, and molecular mechanisms of drug resistance in AML. Key themes include exploiting genetic dependencies, ROS regulation, and targeting oncogenic pathways.

Labs/Teams: Active in the Molecular Oncology Group, collaborating with international teams on clinical trial underpinnings (e.g., Phase II trials for DMG).